GALENAGEN
DEAD

Serial Number

90392963

Owner

Galenagen, LLC

Attorney

Nicole K. McLaughlin

Filing Date

Dec 18, 2020

Add to watchlist:

No watchlists yet
View on USPTO

GALENAGEN Trademark

Serial Number: 90392963

GALENAGEN is a trademark filed by Galenagen, LLC on December 18, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Galenagen, LLC (3 trademarks)

800 Westchester Avenue
Rye Brook, NY 10573

Entity Type: 16

Trademark Details

Filing Date

December 18, 2020

Registration Date

Not Registered

Published for Opposition

August 10, 2021

Goods & Services

Pharmaceutical preparations and substances for the diagnosis, treatment and prevention of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; pharmaceutical preparations for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Antibacterial, antiviral and antifungal preparations for skin and wound healing; disinfectants and antiseptics; antimicrobial cleansers for sanitation purposes; Medical assays for testing of bodily fluids and tissues for testing of enzymes in humans; biological preparations for medical testing; diagnostic preparations for medical purposes; testing kits comprised of medical diagnostic reagents and assays for testing enzymes and body fluids for use in disease detection; medical diagnostic reagents and assays for testing of enzymes and body fluids; chemical preparations for medical testing; diagnostic biomarker reagents for medical testing; all the foregoing for the diagnosis and treatment of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders

Medical testing for diagnostic and treatment purposes; Medical consultations; medical testing for diagnostic treatment purposes in the fields of viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; medical testing for diagnostic treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; Medical diagnostic testing, monitoring and reporting services; performing diagnosis of diseases; Health care services, namely, the administration of medical assays for the detection of enzymes in humans

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical research; Development of pharmaceuticals and medical devices for others; Providing temporary use of non-downloadable computer software that allows users to make determinations regarding neurological diseases, specifically baseline staging, data gathering and monitoring of early, middle and late stage neurological diseases; Design and development of medical assays for others; clinical research and development of treatments for viral, bacterial, fungal, parasitic metabolic, endocrine, hepatological, respiratory, nervous system, neurological, gastrointestinal, digestive, inflammatory, pulmonary, hormonal, dermatological, psychiatric, addictive, behavioral, infectious, addictive, musculoskeletal, cardiovascular, ophthalmic, cardiopulmonary, genitourinary, sexual dysfunction, oncological and immune system related diseases and disorders; clinical research and development of treatments for the treatment and prevention of Influenza, Coronaviruses, pancreatic deficiencies, gastrointestinal disease, internal malabsorption syndromes, Autism, Autism Spectrum Disorder, Attention Deficit Hyperactivity Disorder and Williams Syndrome; clinical research and development of treatments for antibacterial, antiviral, and antifungal preparations for skin and wound healing; clinical research and development of disinfectants, antiseptics and antimicrobial cleansers for sanitation purposes; medical and scientific research services in the field of digestion and detection of enzymes or biological substances in the body

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 11, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 11, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 3, 2024 EXRA
SOU EXTENSION 5 GRANTED
Apr 2, 2024 EX5G
SOU EXTENSION 5 FILED
Apr 2, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
Apr 2, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 4, 2023 EXRA
SOU EXTENSION 4 GRANTED
Oct 2, 2023 EX4G
SOU EXTENSION 4 FILED
Oct 2, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Oct 2, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 31, 2023 EXRA
SOU EXTENSION 3 GRANTED
Mar 29, 2023 EX3G
SOU EXTENSION 3 FILED
Mar 29, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
Mar 29, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 4, 2022 EXRA
SOU EXTENSION 2 GRANTED
Sep 30, 2022 EX2G
SOU EXTENSION 2 FILED
Sep 30, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Sep 30, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 30, 2022 EXRA
SOU EXTENSION 1 GRANTED
Mar 28, 2022 EX1G
SOU EXTENSION 1 FILED
Mar 28, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Mar 28, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 5, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 10, 2021 NPUB
PUBLISHED FOR OPPOSITION
Aug 10, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 21, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 8, 2021 CNSA
ASSIGNED TO EXAMINER
Jun 14, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 1, 2021 NWOS
NEW APPLICATION ENTERED
Dec 22, 2020 NWAP